Inhibition of Ras-mediated cell proliferation by benzyloxybenzaldehyde.

Shiow Lin Pan, Jih Hwa Guh, Ying Wen Huang, Ya Ling Chang, Chiung Yun Chang, Li Jiau Huang, Sheng Chu Kuo, Che Ming Teng

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Excessive proliferation of vascular smooth muscle cells (VSMC) in the intima is an important etiologic factor in vascular proliferative disorders such as atherosclerosis and restenosis after balloon angioplasty. Therefore, control of VSMC growth may be a suitable therapeutic intervention in vascular proliferative disorders. In the present work, we have studied the 2-benzyloxybenzaldehyde (CCY1a)-mediated antiproliferative effect and its mechanisms of action. CCY1a inhibited serum-induced VSMC proliferation in a concentration-dependent manner, as demonstrated using [(3)H]thymidine incorporation and MTT assays; the IC(50) values were calculated to be 7.0 x 10(-6) and 1.2 x 10(-5) M, respectively. Furthermore, it also significantly suppressed serum-induced progression of the cell cycle, as shown by flow cytometric analysis. CCY1a as well as PD98059 almost completely abolished serum-induced activation of p42/44 mitogen-activated protein kinase (MAPK), the downstream effectors of c-fos and c-jun mRNA expression and activator protein-1 (AP-1) DNA binding activity, suggesting the central roles of these signaling cascades. Interestingly, CCY1a also effectively blocked serum-induced Ikappa B-alpha phosphorylation, Ikappa B-alpha degradation and nuclear factor-kappa B (NF-kappa B) binding activity. Based on these observations, we examined the effect of CCY1a on serum-mediated Ras activity, an upstream regulator of the above signaling events. The data demonstrated a marked inhibition of Ras activation by CCY1a. We conclude that CCY1a blocks cell proliferation via inhibition of the upstream effector of Ras and downstream events, including p42/44 MAPK activation and c-fos and c-jun mRNA expression, as well as NF-kappa B and AP-1 DNA binding activities.

Original languageEnglish
Pages (from-to)622-630
Number of pages9
JournalJournal of Biomedical Science
Volume9
Issue number6 Pt 2
Publication statusPublished - Nov 2002
Externally publishedYes

Fingerprint

Cell proliferation
Muscle
NF-kappa B
Chemical activation
Transcription Factor AP-1
Cell Proliferation
Mitogen-Activated Protein Kinases
Vascular Smooth Muscle
Smooth Muscle Myocytes
Serum
Cells
Mitogen-Activated Protein Kinase 1
Messenger RNA
Phosphorylation
DNA
Balloons
Cell growth
Thymidine
Assays
Balloon Angioplasty

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Pan, S. L., Guh, J. H., Huang, Y. W., Chang, Y. L., Chang, C. Y., Huang, L. J., ... Teng, C. M. (2002). Inhibition of Ras-mediated cell proliferation by benzyloxybenzaldehyde. Journal of Biomedical Science, 9(6 Pt 2), 622-630.

Inhibition of Ras-mediated cell proliferation by benzyloxybenzaldehyde. / Pan, Shiow Lin; Guh, Jih Hwa; Huang, Ying Wen; Chang, Ya Ling; Chang, Chiung Yun; Huang, Li Jiau; Kuo, Sheng Chu; Teng, Che Ming.

In: Journal of Biomedical Science, Vol. 9, No. 6 Pt 2, 11.2002, p. 622-630.

Research output: Contribution to journalArticle

Pan, SL, Guh, JH, Huang, YW, Chang, YL, Chang, CY, Huang, LJ, Kuo, SC & Teng, CM 2002, 'Inhibition of Ras-mediated cell proliferation by benzyloxybenzaldehyde.', Journal of Biomedical Science, vol. 9, no. 6 Pt 2, pp. 622-630.
Pan SL, Guh JH, Huang YW, Chang YL, Chang CY, Huang LJ et al. Inhibition of Ras-mediated cell proliferation by benzyloxybenzaldehyde. Journal of Biomedical Science. 2002 Nov;9(6 Pt 2):622-630.
Pan, Shiow Lin ; Guh, Jih Hwa ; Huang, Ying Wen ; Chang, Ya Ling ; Chang, Chiung Yun ; Huang, Li Jiau ; Kuo, Sheng Chu ; Teng, Che Ming. / Inhibition of Ras-mediated cell proliferation by benzyloxybenzaldehyde. In: Journal of Biomedical Science. 2002 ; Vol. 9, No. 6 Pt 2. pp. 622-630.
@article{298e5bd75cb94b30baf7626345c3225d,
title = "Inhibition of Ras-mediated cell proliferation by benzyloxybenzaldehyde.",
abstract = "Excessive proliferation of vascular smooth muscle cells (VSMC) in the intima is an important etiologic factor in vascular proliferative disorders such as atherosclerosis and restenosis after balloon angioplasty. Therefore, control of VSMC growth may be a suitable therapeutic intervention in vascular proliferative disorders. In the present work, we have studied the 2-benzyloxybenzaldehyde (CCY1a)-mediated antiproliferative effect and its mechanisms of action. CCY1a inhibited serum-induced VSMC proliferation in a concentration-dependent manner, as demonstrated using [(3)H]thymidine incorporation and MTT assays; the IC(50) values were calculated to be 7.0 x 10(-6) and 1.2 x 10(-5) M, respectively. Furthermore, it also significantly suppressed serum-induced progression of the cell cycle, as shown by flow cytometric analysis. CCY1a as well as PD98059 almost completely abolished serum-induced activation of p42/44 mitogen-activated protein kinase (MAPK), the downstream effectors of c-fos and c-jun mRNA expression and activator protein-1 (AP-1) DNA binding activity, suggesting the central roles of these signaling cascades. Interestingly, CCY1a also effectively blocked serum-induced Ikappa B-alpha phosphorylation, Ikappa B-alpha degradation and nuclear factor-kappa B (NF-kappa B) binding activity. Based on these observations, we examined the effect of CCY1a on serum-mediated Ras activity, an upstream regulator of the above signaling events. The data demonstrated a marked inhibition of Ras activation by CCY1a. We conclude that CCY1a blocks cell proliferation via inhibition of the upstream effector of Ras and downstream events, including p42/44 MAPK activation and c-fos and c-jun mRNA expression, as well as NF-kappa B and AP-1 DNA binding activities.",
author = "Pan, {Shiow Lin} and Guh, {Jih Hwa} and Huang, {Ying Wen} and Chang, {Ya Ling} and Chang, {Chiung Yun} and Huang, {Li Jiau} and Kuo, {Sheng Chu} and Teng, {Che Ming}",
year = "2002",
month = "11",
language = "English",
volume = "9",
pages = "622--630",
journal = "Journal of Biomedical Science",
issn = "1021-7770",
publisher = "BioMed Central",
number = "6 Pt 2",

}

TY - JOUR

T1 - Inhibition of Ras-mediated cell proliferation by benzyloxybenzaldehyde.

AU - Pan, Shiow Lin

AU - Guh, Jih Hwa

AU - Huang, Ying Wen

AU - Chang, Ya Ling

AU - Chang, Chiung Yun

AU - Huang, Li Jiau

AU - Kuo, Sheng Chu

AU - Teng, Che Ming

PY - 2002/11

Y1 - 2002/11

N2 - Excessive proliferation of vascular smooth muscle cells (VSMC) in the intima is an important etiologic factor in vascular proliferative disorders such as atherosclerosis and restenosis after balloon angioplasty. Therefore, control of VSMC growth may be a suitable therapeutic intervention in vascular proliferative disorders. In the present work, we have studied the 2-benzyloxybenzaldehyde (CCY1a)-mediated antiproliferative effect and its mechanisms of action. CCY1a inhibited serum-induced VSMC proliferation in a concentration-dependent manner, as demonstrated using [(3)H]thymidine incorporation and MTT assays; the IC(50) values were calculated to be 7.0 x 10(-6) and 1.2 x 10(-5) M, respectively. Furthermore, it also significantly suppressed serum-induced progression of the cell cycle, as shown by flow cytometric analysis. CCY1a as well as PD98059 almost completely abolished serum-induced activation of p42/44 mitogen-activated protein kinase (MAPK), the downstream effectors of c-fos and c-jun mRNA expression and activator protein-1 (AP-1) DNA binding activity, suggesting the central roles of these signaling cascades. Interestingly, CCY1a also effectively blocked serum-induced Ikappa B-alpha phosphorylation, Ikappa B-alpha degradation and nuclear factor-kappa B (NF-kappa B) binding activity. Based on these observations, we examined the effect of CCY1a on serum-mediated Ras activity, an upstream regulator of the above signaling events. The data demonstrated a marked inhibition of Ras activation by CCY1a. We conclude that CCY1a blocks cell proliferation via inhibition of the upstream effector of Ras and downstream events, including p42/44 MAPK activation and c-fos and c-jun mRNA expression, as well as NF-kappa B and AP-1 DNA binding activities.

AB - Excessive proliferation of vascular smooth muscle cells (VSMC) in the intima is an important etiologic factor in vascular proliferative disorders such as atherosclerosis and restenosis after balloon angioplasty. Therefore, control of VSMC growth may be a suitable therapeutic intervention in vascular proliferative disorders. In the present work, we have studied the 2-benzyloxybenzaldehyde (CCY1a)-mediated antiproliferative effect and its mechanisms of action. CCY1a inhibited serum-induced VSMC proliferation in a concentration-dependent manner, as demonstrated using [(3)H]thymidine incorporation and MTT assays; the IC(50) values were calculated to be 7.0 x 10(-6) and 1.2 x 10(-5) M, respectively. Furthermore, it also significantly suppressed serum-induced progression of the cell cycle, as shown by flow cytometric analysis. CCY1a as well as PD98059 almost completely abolished serum-induced activation of p42/44 mitogen-activated protein kinase (MAPK), the downstream effectors of c-fos and c-jun mRNA expression and activator protein-1 (AP-1) DNA binding activity, suggesting the central roles of these signaling cascades. Interestingly, CCY1a also effectively blocked serum-induced Ikappa B-alpha phosphorylation, Ikappa B-alpha degradation and nuclear factor-kappa B (NF-kappa B) binding activity. Based on these observations, we examined the effect of CCY1a on serum-mediated Ras activity, an upstream regulator of the above signaling events. The data demonstrated a marked inhibition of Ras activation by CCY1a. We conclude that CCY1a blocks cell proliferation via inhibition of the upstream effector of Ras and downstream events, including p42/44 MAPK activation and c-fos and c-jun mRNA expression, as well as NF-kappa B and AP-1 DNA binding activities.

UR - http://www.scopus.com/inward/record.url?scp=0348240878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0348240878&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 622

EP - 630

JO - Journal of Biomedical Science

JF - Journal of Biomedical Science

SN - 1021-7770

IS - 6 Pt 2

ER -